GSK Annual Report 2002
GSK Annual Report 2002
GSK Annual Report 2002
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Financial statements<br />
GlaxoSmithKline 73<br />
This section comprises the Directors’ statements, the independent<br />
auditors’ report on the Financial statements, the Financial<br />
statements consisting of the principal Financial statements and<br />
supporting notes, and additional financial data.<br />
74 Directors’ statements of responsibility<br />
75 Independent Auditors’ report<br />
Financial statements<br />
76 Consolidated statement of profit and loss<br />
76 Consolidated statement of total recognised gains and losses<br />
78 Consolidated statement of cash flow<br />
80 Consolidated balance sheet<br />
80 Reconciliation of movements in equity shareholders’ funds<br />
81 Company balance sheet<br />
82 Notes to the financial statements<br />
1. Presentation of Financial statements<br />
2. Accounting policies<br />
3. New accounting policies and requirements<br />
4. Exchange rates<br />
5. Merger of Glaxo Wellcome and SmithKline Beecham<br />
6. Segment information<br />
7. Merger items, restructuring costs and divested businesses<br />
8. Other operating income/(expense)<br />
9. Operating profit<br />
10. Joint ventures and associated undertakings<br />
11. Net interest payable<br />
12. Taxation<br />
13. Earnings per share<br />
14. Dividends<br />
15. Goodwill<br />
16. Intangible assets<br />
17. Tangible fixed assets<br />
18. Fixed asset investments<br />
19. Equity investments<br />
20. Stocks<br />
21. Debtors<br />
22. Other creditors<br />
23. Provisions for liabilities and charges<br />
24. Contingent liabilities<br />
25. Net debt<br />
26. Commitments<br />
27. Share capital and share premium account<br />
28. Non-equity minority interests<br />
29. Reserves<br />
30. Legal proceedings<br />
31. Acquisitions and disposals<br />
32. Financial instruments and related disclosures<br />
33. Employee costs<br />
34. Employee share schemes<br />
35. Related party transactions<br />
36. GlaxoSmithKline plc investment in subsidiary companies<br />
37. Reconciliation to US accounting principles<br />
38. Principal Group companies<br />
Financial record<br />
142 Quarterly trend<br />
148 Five year record